Biotricity, Inc.

Equities

BTCY

US09074H2031

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
1.3 USD -6.47% Intraday chart for Biotricity, Inc. -12.16% +13.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Premarket Decliners MT
Biotricity, Inc. announced that it has received $2 million in funding CI
Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities CI
Biotricity, Inc. announced a financing transaction CI
Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud CI
Biotricity, Inc. Solidifies It's Presence in the Healthcare Landscape CI
Transcript : Biotricity, Inc., Q3 2024 Earnings Call, Feb 21, 2024
Biotricity, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats CI
HC Wainwright Downgrades Biotricity to Neutral From Buy MT
Transcript : Biotricity, Inc., Q2 2024 Earnings Call, Nov 14, 2023
Biotricity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Biotricity Releases Another Groundbreaking Product: Biotres Pro CI
Biotricity Files Patent for Wearable Heart Monitoring Device Bioheart MT
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device CI
Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device CI
Transcript : Biotricity, Inc., Q1 2024 Earnings Call, Aug 15, 2023
Biotricity, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Biotricity Expands Amazon, Google Partnership for Remote Cardiac Monitoring Technology MT
Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications CI
HC Wainwright Adjusts Biotricity Price Target to $4 From $12 After 1-for-6 Reverse Stock Split, Maintains Buy Rating MT
Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023 CI
HC Wainwright Adjusts Biotricity Price Target to $4 From $12, Maintains Buy Rating MT
Monday's Top Decliners MT
Traders Digest Strong Tesla Delivery Numbers as US Equity Futures Tread Water Ahead of Shortened Session MT
Chart Biotricity, Inc.
More charts
Biotricity Inc. is a medical technology company focused on biometric data monitoring and diagnostic solutions. The Company developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. It has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.3
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. BTCY Stock
  4. News Biotricity, Inc.
  5. Biotricity Secures FDA Clearance for Heart Monitoring Device